📄 Middle east respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus ankara efficiently induces virus-neutralizing antibodies

Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVAMERS- S may serve for further development of an emergency vaccine against MERS-CoV. © 2013, American Society for Microbiology.

keywords 🔗 syndrome coronavirus (1074) 🔗 causative agent (117) 🔗 respiratory syndrome (2004)

download 🔖 [BibTeX]